Study guide
15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety
BONENT Certified Hemodialysis Nurse CHN
Track your progress as you read
Finished sections get a check mark.
1 Exam Orientation
1.1 Current CHN Exam Facts and Study Strategy
2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology
2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD
3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations
3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management
4 Individualized Nursing Care
4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral
5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry
5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR
6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters
6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention
7 Chapter 5: Cannulation Practice & Access Complications
7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management
8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring
8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment
9 Equipment and Laboratory Skills
9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results
10 Chapter 7: Acute Intradialytic Complications & Emergencies
10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss
11 Extended and Acute Treatment
11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation
12 Chapter 8: Nephrology Pharmacology in Hemodialysis
12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing
13 Home and Peritoneal Dialysis
13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care
14 Kidney Transplantation
14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes
15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing
15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety
16 Clinical Unit Management
16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care
17 Chapter 10: Supervision, Administration & Professional Practice
17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care
18 Professional Development
18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation
19 Environmental Hazards and Emergency Planning
19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions
15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety
Key Takeaways Explain This Topic AI
CMS incorporates RD47:2002 with the 2003 amendment for reuse; ST72 is not the reuse standard.
Use a labeled reusable device only for the same identified patient; HBV-positive dialyzers must not be reused.
HCV or HIV alone does not require dedicated machines or automatic reuse exclusion under CDC recommendations.
Verify performance, leak integrity, germicide exposure and residual clearance using the actual product instructions.
Last updated: October 2026
Dialyzer Reprocessing Standards, Testing & Germicide Safety
Dialyzer reuse is a validated same-patient cleaning, testing and disinfection process for a labeled reusable device. It does not guarantee sterility and must meet the incorporated reuse requirements and product instructions.
Patient Eligibility & Absolute Contraindications
A reprocessed dialyzer can only be reused on the specific patient whose blood previously circulated through that dialyzer; sharing or cross-patient reuse is strictly prohibited. Furthermore, strict biological contraindications govern reuse candidacy:
Hepatitis B Surface Antigen Positivity
Patients who test positive for Hepatitis B Surface Antigen ( H B s A g HBsAg H B s A g ) are strictly excluded from dialyzer reprocessing . Because the Hepatitis B virus is exceptionally resilient, exhibits high viral titers in circulating blood, and can be transmitted via minuscule trace inocula, reprocessing an H B s A g HBsAg H B s A g -positive dialyzer carries an unacceptable risk of cross-contaminating automated reuse equipment, header rinse basins, and other patients' dialyzers. Dialyzers used by Hepatitis B-positive patients must be treated as single-use items and discarded as biohazardous waste immediately after treatment.
Hepatitis C, HIV and Same-Patient Reuse
CDC does not require separate machines or special reuse segregation solely for HCV or HIV. Proper dialysis infection precautions and a validated same-patient process are essential. Reuse is permitted only for a reusable FDA-cleared device, the same patient and a process consistent with labeling and §494.50. HBV-positive patients' dialyzers must not be reused. Do not confuse an HCV antibody result with an automatic reuse prohibition, or describe reprocessing as guaranteeing sterility.
Explain the reuse policy and the patient’s rights, and maintain positive patient/device identification through transport, processing, storage and preparation. A damaged label, failed test or uncertain identity excludes the device from use until resolved through the approved process; guessing which patient owns the dialyzer is never acceptable.
Stepwise Mechanical Reprocessing Workflow
Following the conclusion of hemodialysis, the extracorporeal circuit undergoes a structured sequence of steps:
Bedside Post-Treatment Flush : The bloodlines are disconnected, and the dialyzer blood compartment is immediately flushed with normal saline or heparinized saline to displace gross residual blood. Header port caps are applied, and the dialyzer is placed into a labeled, puncture-resistant, leak-proof transport container and transported directly to the reprocessing suite.
Validated cleaning cycle: The reprocessing system clears blood and deposits through its labeled hydraulic and cleaning process. Use only compatible chemicals and approved concentrations; bleach is not appropriate for every membrane or reuse system. Verify rinse completion, device condition and the programmed process rather than substituting a universal cleaning mixture.
Performance & Structural Integrity Testing
Before any dialyzer can be approved for chemical germicide filling and storage, it must successfully pass two automated, non-negotiable physical tests:
1. Total Cell Volume (TCV) / Fiber Bundle Volume (FBV)
Principle : Total Cell Volume measures the internal fluid-holding capacity of the hollow-fiber capillary bundle. Because solute clearance ( K K K ) and ultrafiltration capacity depend directly on available functional membrane surface area, clotted or obstructed fibers reduce TCV.
Baseline Measurement : Prior to its first clinical use, every pristine new dialyzer is filled with RO water to determine its baseline internal volume (Baseline TCV), which is permanently recorded in the dialyzer log and on the dialyzer label.
The 80% Retained Volume Mandate : AAMI and CMS standards dictate that a reprocessed dialyzer must retain ≥ 80 % \ge 80\% ≥ 80% of its original baseline TCV: % Retained TCV = Current Measured TCV Baseline TCV × 100 % \% \text{Retained TCV} = \frac{\text{Current Measured TCV}}{\text{Baseline TCV}} \times 100\% % Retained TCV = Baseline TCV Current Measured TCV × 100%
If the measured TCV falls below 80% (indicating excessive loss of measured bundle volume), the dialyzer must be permanently rejected and discarded . A failed performance criterion disqualifies the device; the measured percentage alone does not calculate the patient’s delivered Kt/V.
2. Membrane Structural Integrity Test (Pressure Leak Test)
High-flux hollow fibers are susceptible to micro-rupture or mechanical shearing during clinical treatments and high-pressure cleaning cycles. A ruptured fiber allows direct, unrestricted mixing of non-sterile dialysate with the patient's bloodstream, creating risks of blood loss and contamination that require rejection of the device.
The reprocessor applies its labeled integrity test and acceptance limits. Review pressure-hold or leak-test results, alarms and device condition. A failed integrity test excludes the device from clinical use; do not bypass the result or independently alter test pressure and duration.
Chemical Germicides & Biocidal Dwell Kinetics
Once the dialyzer passes TCV and pressure leak tests, the automated machine infuses a high-level liquid disinfectant/sterilant into both the blood and dialysate compartments:
1. Peracetic Acid Formulations (e.g., Renalin, Puristeril)
Chemistry : An equilibrium mixture of peracetic acid ( C H 3 C O O O H CH_3COOOH C H 3 COOO H ), hydrogen peroxide ( H 2 O 2 H_2O_2 H 2 O 2 ), and acetic acid ( C H 3 C O O H CH_3COOH C H 3 COO H ). It kills bacterial spores, vegetative bacteria, viruses, and fungi through rapid protein oxidation and free-radical generation.
Minimum chemical exposure and storage time are product-specific; do not apply one formulation’s dwell time to every germicide.
Advantages : Non-carcinogenic; degrades into non-toxic environmentally benign byproducts (water, oxygen, and acetic acid).
2. Formaldehyde (Formol)
Chemistry : A 4% aqueous solution of formaldehyde. It cross-links amino and sulfhydryl groups in bacterial proteins and nucleic acids.
Exposure: Concentration, temperature and dwell follow the validated chemical and reusable-device instructions. Do not shorten exposure by independently heating a product or applying another germicide’s time.
Toxicity : Formaldehyde is a known human volatile carcinogen and potent respiratory allergen. OSHA mandates strict workplace vapor monitoring (Permissible Exposure Limit [PEL] of 0.75 ppm as an 8-hour time-weighted average, with an action level of 0.5 ppm).
3. Glutaraldehyde (e.g., Diacide)
Glutaraldehyde: A sensitizing chemical used in some validated processes. Concentration, exposure and compatibility follow the actual label; one ten-to-twelve-hour dwell is not a universal requirement.
Pre-Dialysis Verification & Clinical Safety Testing
Qualified staff perform the facility’s positive-identity and release-verification process; two licensed clinicians are not a universal federal requirement.
Patient Identification Check : Verify that the patient's full legal name, medical record number, dialyzer model, reuse number, and expiration date on the dialyzer label match the patient's medical chart and treatment sheet exactly.
Germicide presence/concentration: Confirm the approved agent, concentration, exposure and required pre-rinse test. A failed result requires the approved rejection or corrective process; a presence test alone neither proves sufficient dwell nor guarantees sterility.
Saline Rinse-Out & Prime : The dialyzer is connected to the extracorporeal circuit on the dialysis machine. Rinse the compartments with the labeled solutions and volumes using the approved sequence. A fixed 1–2-L saline volume is not sufficient evidence of clearance for every device and chemical; residual testing determines readiness under the release protocol.
Residual germicide test: Obtain the specified sample using the correct test and labeled acceptance limit before patient connection. Product-specific residual limits differ; do not substitute a test for another chemical.
Warning
The Potting Material Rebound Phenomenon: Use the product-specific residual and rebound-testing procedure before clinical use; timing is not universal.
Germicide Comparison Matrix
Germicide Agent Minimum Dwell Time Biocidal Mechanism Residual Safety Limit Clinical Trade-offs
Peracetic-acid mixture Label-specific exposure Oxidation Agent-specific residual test Compatible process, ventilation and PPE required
Formaldehyde Label-specific exposure Protein/nucleic-acid reactions Agent-specific residual test OSHA vapor limits and carcinogenicity require exposure controls
Glutaraldehyde Label-specific exposure Protein cross-linking Agent-specific residual test Skin and respiratory sensitization require controls
Germicide concentration, minimum exposure, shelf life, rinse and rebound-testing requirements follow the actual reusable dialyzer and chemical label. An eleven-hour Renalin example is not the dwell time for every peracetic-acid product; formaldehyde and other agents also require their own validated instructions. Staff verification requires qualified personnel and the facility’s identity-check process, not a universal requirement for two licensed nurses. Document original and current cell volume, leak-test results, cycle count, chemical lot, exposure time, residual clearance and release decision. If current volume is 92 mL from an original 120 mL, retained volume is 76.7%, below an 80% acceptance criterion. Do not round that result into a pass.
Sources checked 2026-10-10: CMS Part 494
Device source checked 2026-10-11: Fresenius operator manuals, including 2008T revision AE . Examples explain principles; the actual device and chemical labeling govern operation.